- Home
- USIO vs BLRX Comparison
USIO vs BLRX Comparison
Compare USIO & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- BLRX
- Stock Information
- Founded
- USIO 1998
- BLRX 2003
- Country
- USIO United States
- BLRX Israel
- Employees
- USIO N/A
- BLRX N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- BLRX Health Care
- Exchange
- USIO Nasdaq
- BLRX Nasdaq
- Market Cap
- USIO 37.8M
- BLRX 36.0M
- IPO Year
- USIO N/A
- BLRX 2011
- Fundamental
- Price
- USIO $1.47
- BLRX $0.28
- Analyst Decision
- USIO Strong Buy
- BLRX Strong Buy
- Analyst Count
- USIO 2
- BLRX 2
- Target Price
- USIO $5.00
- BLRX $11.50
- AVG Volume (30 Days)
- USIO 81.8K
- BLRX 1.2M
- Earning Date
- USIO 11-06-2024
- BLRX 11-25-2024
- Dividend Yield
- USIO N/A
- BLRX N/A
- EPS Growth
- USIO N/A
- BLRX N/A
- EPS
- USIO 0.13
- BLRX N/A
- Revenue
- USIO $81,027,258.00
- BLRX $17,048,000.00
- Revenue This Year
- USIO $4.13
- BLRX N/A
- Revenue Next Year
- USIO $13.76
- BLRX N/A
- P/E Ratio
- USIO $11.08
- BLRX N/A
- Revenue Growth
- USIO N/A
- BLRX N/A
- 52 Week Low
- USIO $1.30
- BLRX $0.26
- 52 Week High
- USIO $2.00
- BLRX $1.89
- Technical
- Relative Strength Index (RSI)
- USIO 54.32
- BLRX 30.89
- Support Level
- USIO $1.40
- BLRX $0.44
- Resistance Level
- USIO $1.55
- BLRX $0.56
- Average True Range (ATR)
- USIO 0.06
- BLRX 0.04
- MACD
- USIO 0.00
- BLRX -0.01
- Stochastic Oscillator
- USIO 61.90
- BLRX 5.37
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.